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a  b  s  t  r  a  c  t
A  patient  experiencing  chronic  New York  Heart  Association  (NYHA)  Class  III heart  failure  with reduced
left  ventricular  ejection  fraction  and  signs  of  right  ventricular  dysfunction  is treated  with baroreﬂex
activation  therapy  (BAT).  Despite  optimal  medical  therapy,  the  patient  had  repeatedly  decompensated
and  was  approaching  a refractory  terminal  stage.  BAT  chronically  reduced  muscle  sympathetic  nerve
activity  and dramatically  improved  clinical  presentation  of  the  patient  to  NYHA  Class  I  through  12  months
of  therapy.  BAT  may  hold  promise  for patients  with  advanced  heart  failure  and  reduced  ejection  fraction
who  have  exhausted  conventional  therapy  options.on-pharmacologic therapy
aroreﬂex
<Learning objective:  Activation  of the  baroreﬂex  via  stimulation  of  the  carotid  sinus acutely  improves
hemodynamics  and  chronically  improves  the  clinical  course  of  a patient  with  heart  failure  and  reduced
ejection  fraction.  The  patient  transitions  from  near  end-stage  New  York  Heart  Association  Class  III to
Class  I  at  12  months  of  therapy.  The  baroreﬂex  pathway  may  be  a  viable  option  for  treatment  of  heart
failure  patients.>
©  2014  Japanese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroduction
Refractory end-stage heart failure (HF) is a lethal condition
ith limited treatment options. Extant device therapies such as
mplanted cardioverter-deﬁbrillators, resynchronization therapy,
nd left ventricular assist devices beneﬁt certain cohorts but many
atients must solely rely on optimal medical therapy. Clinical appli-
ation of autonomic modulation by direct neural intervention is a
urgeoning ﬁeld for treatment of HF: renal nerve ablation removes
eural endings from target organs while vagal nerve stimulation
nd baroreﬂex activation therapy (BAT) restore physiological car-
iac neural trafﬁc.
A  randomized, controlled trial has previously demonstrated the
eneﬁt of BAT in resistant hypertension [1]. BAT has also shown
eneﬁt in a case of hypertensive HF [2] and animal models of HF [3].
he rationale for BAT in HF has been detailed [4]. Brieﬂy, activation
f the baroreﬂex restores sympathovagal balance, which results
∗ Corresponding author at: IRCCS MultiMedica, Via Milanese 300, 20 141 Milano,
taly.  Tel.: +39 0224209460; fax: +39 0224209051.
E-mail address: edoardo.gronda@multimedica.it (E. Gronda).
ttp://dx.doi.org/10.1016/j.jccase.2014.02.007
878-5409/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights rein relaxation of vascular smooth muscle, improved ventricular-
vascular coupling, reduced cardiac ﬁlling pressures and metabolic
demand, and increased venous capacitance and natriuresis through
suppression of the renin–angiotensin–aldosterone system.
Case  report
A  69-year-old Caucasian male presented in April 2012 with
New York Heart Association (NYHA) Class III HF with reduced
ejection fraction (HFrEF), signs of right ventricular failure, stage
3 chronic kidney disease, insulin dependent diabetes, and body
mass index of 22 kg/m2. The patient experienced hospitalizations
3 and 4 months prior to worsening HF lasting 7 and 17 days,
respectively. Decompensations were characterized by signiﬁcant
hepatic and splanchnic congestion. History included chronic
hypertension, sinus node dysfunction, anemia, coronary artery
by pass surgery in 1988, anterior myocardial infarction in 2005,
and a later percutaneous transluminal coronary angioplasty with
vein graft stenting. The patient had contraindication to the use
of beta-blockade (sick sinus node syndrome), but was on stable,
guideline-directed optimal medical therapy: ramipril 1.25 mg  QD,
torasemide 10 mg  QD, digoxin 0.125 mg  QD, aspirin 100 mg  QD,
served.
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Table  1
Timeline of clinical variables before and after initiation of baroreﬂex activation therapy. Muscle sympathetic nerve activity was acquired by microneurography just prior to
implant  and after 3 and 6 months of therapy.
January 2012 February 2012 April 2012 July 2012 November 2012 May  2013
ADHF Discharge ADHF Discharge Pre-implant Month 3 Month 6 Month 12
NYHA Class IV III IV III III II I I
Weight  (kg) 69  69 69 72
Blood  pressure (mmHg) 120/60 110/70 100/60 100/60 120/60 110/70 115/70 115/70
Heart  rate (bpm) 66 70 70 70 66 62 64 72
QRS  duration (ms) 120 130 132
Hemoglobin  (g/dL) 14.0 12.2 13.4
Creatinine  (mg/dL) 2.71 2.04 2.86 1.54 1.73 1.97 1.96
eGFR  (mL/min/1.73 m2) 24.78 34.39 23.42 47.57 41.83 35.90 36.01
BNP  (pg/mL) 1718  1390 999 1054 966 393
Bilirubin:  direct/indirect (mg/dL) 0.43/0.47
LVEF (%) 37 40 42 44
LVEDV  (mL) 146 170 186 188
EPASP  (mmHg) 50 50 50 42
IVC  inspiratory diameter (cm) 2.20 2.16 1.05
IVC  expiratory diameter (cm) 2.60 2.59 1.93
6MHWT  (m)  330 450 375 400
MSNA  (burst/min) 37 20.3 18.7
MSNA  (burst/100 beats) 68 31.5 30.1
ADHF, time of admission to the hospital for acute decompensated heart failure; NYHA, New York Heart Association; eGFR, estimated glomerular ﬁltration rate; BNP, B-type
n nd-d
v tivity.
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datriuretic peptide; LVEF, left ventricular ejection fraction; LVEDV, left ventricular e
ena  cava; 6MHWT, six-minute hall walk test; MSNA, muscle sympathetic nerve ac
errous sulfate/ascorbic acid 105 g QD, and insulin aspart 16 IU
ID. Having exhausted conventional therapies and not fulﬁlling
ligibility criteria for cardiac resynchronization therapy (QRS
uration <120 ms), he consented to participate in an open-label
easibility study of BAT for the treatment of HFrEF. The study
as approved by the local ethics committee and its design was
n accordance with the Declaration of Helsinki. Clinical data were
aken from medical history and per protocol (Table 1).
The  BarostimTM neo system (CVRx, Inc., Minneapolis, MN,  USA)
as implanted with the pulse generator in the right pectoral region
nd the single lead on the ipsilateral carotid sinus. Hemodynamics
ere monitored by Swan-Ganz catheter during acute low-intensity
AT. Cardiac output increased from 4.5 to 4.9 L/min, with pul-
onary artery systolic and wedge pressures dropping from 48 to
9 mmHg  and 24 to 20 mmHg, respectively. Heart rate and arte-
ial blood pressure did not appreciably change. No procedure- or
evice-related complications occurred.
Chronic BAT began 15 days post-implant and continued through
2 months of follow-up with dose titration monthly through the
rst 4 months. Muscle sympathetic nerve activity was chroni-
ally reduced through 6 months. Six-minute hall walk distance,
YHA Class and serum B-type natriuretic peptide concomitantly
mproved. NYHA Class remained constant between Month 6 and 12
t Class I. Blood pressure, heart rate, left ventricular ejection frac-
ion and size, and renal function remained stable. No procedure-
r device-related complications occurred. Emergency surgery for
cute incarcerated hernia during chronic BAT was well-tolerated.
iscussion
BAT  produced a marked amelioration in HF symptoms without
 signiﬁcant change in left ventricular size. This ﬁnding should not
e of surprise as the primary mechanism for the efﬁcacy of BAT
n heart failure is probably a regionally-coordinated reduction in
ympathetic nerve trafﬁc to the heart, arteries, veins, kidneys, and
iscera [4]. The result of this neuromodulatory shift is a reduced
rterial resistance, an increased beat-to-beat interval, and venous
apacitance while venous return is maintained. This would result
n an increased stroke work and a reduced myocardial oxygen
emand. Extra-cardiac effects which are of key importance in HFiastolic volume; EPASP, estimated pulmonary artery systolic pressure; IVC, inferior
include transfer of blood volume from the central compartment
to the splanchnic circulation, increased skeletal muscle perfu-
sion, and enhanced natriuresis. Clinically, these changes would be
expected to reduce edema and dyspnea and increase functional
capacity.
As the clinical course described in Table 1 indicates, many of
these changes were observed chronically in the patient: sympa-
thetic tone diminished, overall clinical presentation improved,
functional capacity increased, and a biomarker of ventricular
wall stress decreased. Acute activation demonstrated increased
cardiac output at reduced pulmonary and wedge pressures,
thereby conﬁrming expected changes in central hemodynam-
ics. Freedom from congestion and decompensation throughout
follow-up suggests that BAT was  chronically effective at transfer-
ring volume away from the central compartment and promoting
natriuresis.
Conclusions
BAT substantially improved the clinical course of a post-
myocardial infarction HFrEF patient with recent, repeated, and
lengthy hospitalizations for worsening HF. Prior to implant,
prognosis was  poor given the recent history of hospitalization
and concomitant right ventricular impairment. Sympathetic
tone diminished with BAT while clinical presentation, functional
capacity, and ventricular wall stress improved. Results were
striking as the patient had been approaching refractory end-
stage HF despite optimal medical therapy. No safety concerns
were associated with BAT. This case highlights the potential of
systemic neuromodulation by BAT as a powerful new approach
for treatment of advanced HF. Randomized, controlled trials are
underway to validate safety and efﬁcacy of BAT in a broader HFrEF
population.
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